TY - JOUR T1 - Cost of hypertension illness and associated factors among patients attending hospitals in Southwest Shewa Zone, Oromia Regional State, Ethiopia JF - medRxiv DO - 10.1101/2019.12.17.19015198 SP - 2019.12.17.19015198 AU - Addisu Bogale AU - Teferi Daba AU - Dawit Wolde Daka Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/12/21/2019.12.17.19015198.abstract N2 - Background Hypertension is a common vascular disease and the main risk factor for cardiovascular diseases. The impact of hypertension is on the rise in Ethiopia, so that, it is predictable that the cost of healthcare services will further increase in the future. We aimed to estimate the total cost of hypertension illness among patients attending hospitals in Southwest Shewa zone, Oromia Regional State, Ethiopia.Patients and methods Institution based cross-sectional study was conducted from July 1-30, 2018. All hypertensive patients who were on treatment and whose age was greater than eighteen years old were eligible for this study. The total cost of hypertension illness was estimated by summing up the direct and indirect costs. Bivariate and multivariate linear regression analysis was conducted to identify factors associated with hypertension costs of illness.Results Overall, the mean monthly total cost of hypertension illness was US $ 22.3 (95% CI, 21.3-23.3). Direct and indirect costs share 51% and 49% of the total cost, respectively. The mean total direct cost of hypertension illness per patient per month was US $11.39(95% CI, 10.6-12.1). Out of these, drugs accounted of a higher cost (31%) followed by food (25%). The mean total indirect cost per patient per month was US $10.89(95% CI, 10.4-11.4). Educational status, distance from hospital, the presence of companion and the stage of hypertension were predictors of the cost of illness of hypertension.Conclusion The cost of hypertension illness was very high when compared with the mean monthly income of the patients letting patients to catastrophic costs. Therefore, due attention should be given by the government to protect patients from financial hardships.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe funding organization was Jimma university and the funder have no any role in the design, data collection, analysis and publication of this paper.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesResearch data were available and can be accessed from the indicated addresses (E-mail: dave86520@gmail.com or dawit818@yahoo.com) ER -